Breast Cancer

SystHERs HER2+ Breast Observational
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer

PECCY Paclitaxel +/- GDC-0941 HR+ Her2-mBC
A Phase II, Randomized Study of Paclitaxel with GDC-0941 Versus Paclitaxel with Placebo in Patients with Locally Recurrent or Metastatic Breast Cancer

Palbociclib Post AI HR+ Her2- mBC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Fulvestrant (Faslodex®) with or without PD-0332991 Palbociclib) ± Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy Pfizer

BMN673 vs PhyChoice gBRCA met Br
A Phase III, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease

Leukemia

CML Observational Trial - SIMPLICITY
Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

Nilot Discon-CML Pts in MMR on imat>1yr
A Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching toNilotinib

Lung Cancer

LDK378 v SOC ALK+ NSCLC Post Chemo/Criz
A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Lymphomas

Brentuximab Vedotin in Older Pts with HL
A Phase II Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Brentux, CD30-Neg. in Ripsd LgCell Lymph
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Trabectedin +/- PLD Adv Ovarian 2/3 In
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Prostate

XL184 +Abiraterone w Bone Mets in cRPC
A Randomized Phase II Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naive Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer

Select Tumors or Hematological Malignancies

PI3K Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - BKM120 for Patients with PI3K-Activated Tumors

Solid Tumors

Signature Series: FGFR Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFRI, Trk and RET